Crescent Biopharma (CBIO) has priced an underwritten offering of about 8.1 million common shares and, for certain investors, pre-funded warrants to purchase up to 525,897 common shares at $14.50 each, the cancer-treatment company said late Tuesday.

Underwriters have been granted a 30-day option to purchase up to about 1.3 million additional shares.

Crescent Biopharma expects to raise $125 million from the offering, which is slated to close Thursday.